• Publications
  • Influence
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
Treatment with epratuzumab plus standard reinduction chemotherapy is feasible and acceptably tolerated in children with relapsed CD22-positive ALL and CD22 targeting was efficient, and the majority of patients achieved favorable early responses.
Targeted therapy of cancer with radiolabeled antibodies.
  • D. Goldenberg
  • Medicine
    Journal of nuclear medicine : official…
  • 1 May 2002
Although RAIT of solid tumors has shown less progress, pretargeting strategies, such as an affinity-enhancement system consisting of bispecific antibodies separating targeting from delivery of the radiotherapeutic, appear to enhance tumor-to-nontumor ratios and may increase rad doses to tumor more selectively than directly labeled antibodies.
Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma
It is demonstrated that epratuzumab has a good safety profile and exerts antitumor activity in aggressive non-Hodgkin’s lymphoma at doses of ≥240 mg/m2, thus warranting further evaluation in this clinical setting.
Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
How antibodies and immunoconjugates have influenced cancer detection and therapy is reviewed, and promising new developments and challenges for broader applications are described.
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
A 43% objective response rate in follicular NHL patients treated at 360 mg/m2/wk indicates that this dose should be explored in additional studies, and well tolerated epratuzumab was well tolerated at up to 1,000mg/m 2/wk (for 4 weeks) and had clinical activity.
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
In patients with mild to moderate active lupus, epratuzumab was well tolerated, with evidence of clinical improvement after the first infusion and durable clinical benefit across most body systems, and multicenter controlled studies are being conducted in broader patient populations.
Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives.
A variety of basic compounds is capable of inhibiting the tubular reabsorption of peptides and proteins, thus lowering the kidney uptake of antibody fragments significantly, and their role as imaging and therapeutic agents may be expanded.
CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms
Preclinical evaluations of LL1, its humanized form, and isotope, drug, and toxin conjugate show that unconjugated hLL1 and conjugates of h LL1 constructs with radioisotopes, doxorubicin, and frog RNase have high antitumor activity in non–Hodgkin's lymphoma and multiple myeloma in vitro and in tumor xenograft models.
Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers
CEACAM6 expression is elevated in many solid tumors, but variable as a function of histotype, and may be a promising target for antibody-based therapy.
Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer
It is shown that sacituzumab govitecan‐hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple‐negative breast cancer and was also associated with clinical benefit rate and overall survival.